Assistant Professor, Medicine, University of Pittsburgh School of Medicine
Hematology
Dr. Rachel C. Jankowitz, MD
|
|
Give Review
Rachel C. Jankowitz works in the field of Hematology. She graduated from Temple University School of Medicine. Rachel Jankowitz is a published doctor. She published 18 publications, including: 'Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial.' Rachel C. Jankowitz accepts all Medicare patients.
Publications
- Prevention of bone loss with risedronate in breast Cancer survivors: a randomized, controlled clinical trial.
- Apolipoprotein e genotype and cognitive function in postmenopausal women with early-stage breast Cancer.
- Should We Embrace or Ablate Our Urge to (Ovarian) Suppress?
- Epigenetic reprogramming in breast Cancer: From new targets to new therapies.
- Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast Cancer.
- Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast Cancer: an NSABP Foundation Resear...
- Breast Cancer index identifies early-stage estrogen receptor-positive breast Cancer patients at risk for early- and late-distant recurrence.
- The evolving role of multi-gene tests in breast Cancer management.
- Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.
- Adjuvant treatment of HER2-positive breast Cancer: winning efforts continue to improve HER2-positive patient outcome long-term.
- Prognostic utility of the breast Cancer index and comparison to Adjuvant! Online in a clinical case series of early breast Cancer.
- Adjuvant endocrine therapy for breast Cancer: don't ditch the switch!
- A Putative Case of Methotrexate-Related Lymphoma: Clinical Course and PET/CT Findings.
- A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease.
- Anaphylaxis after administration of ibritumomab tiuxetan for follicular non-hodgkin lymphoma.
- Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia.
- Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma.
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Breast Cancer
- Carcinoma in Situ
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Education
-
University of Pittsburgh Medical Center -
Temple University School of Medicine
Hospital
-
UPMC Presbyterian Shadyside
Drug Facts
| NPI NUMBER | 1104027218 | |
| NPPES Provider LastName | JANKOWITZ | |
| NPPES Provider FirstName | RACHEL | |
| NPPES Provider ZIPCode | 152133108 | |
| NPPES Provider State | PA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 527.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 12.0 | |
| Percent Opioid Claims | 2.28 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1104027218 |
| Last Name Of The Provider | JANKOWITZ |
| First Name Of The Provider | RACHEL |
| View All |
Similar Doctors
|
|
Dr. Elana J. Bloom, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Leonard J. Appleman, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Robert L. Volkin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Entezam A. Sahovic, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Hussein A. Tawbi, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Mark A. Socinski, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Rahul A. Parikh, MD |